Silk Road Medical, Inc (SILK)
- Previous Close
27.49 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 27.51 - Volume
0 - Avg. Volume
1,138,278 - Market Cap (intraday)
1.117B - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.45 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.75
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
silkroadmed.comRecent News: SILK
View MoreResearch Reports: SILK
View MorePerformance Overview: SILK
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SILK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SILK
View MoreValuation Measures
Market Cap
1.12B
Enterprise Value
1.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.63
Price/Book (mrq)
7.22
Enterprise Value/Revenue
5.34
Enterprise Value/EBITDA
-12.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.53%
Return on Assets (ttm)
-14.11%
Return on Equity (ttm)
-36.45%
Revenue (ttm)
191.43M
Net Income Avi to Common (ttm)
-56.54M
Diluted EPS (ttm)
-1.45
Balance Sheet and Cash Flow
Total Cash (mrq)
171.98M
Total Debt/Equity (mrq)
54.61%
Levered Free Cash Flow (ttm)
-15.35M